Online inquiry

IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5440MR)

This product GTTS-WQ5440MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets tcdA gene. The antibody can be applied in Clostridium difficile infectious diarrhea research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq WP_009902072.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57299391
UniProt ID P16154
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5440MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1437MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACC-001
GTTS-WQ13220MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-05082566
GTTS-WQ7883MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-249320
GTTS-WQ6969MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ3257MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ART621
GTTS-WQ12167MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MORAb-009
GTTS-WQ13714MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RC48
GTTS-WQ13046MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PEG-IFN-SA
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW